Clinical trial
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
NCT03455439 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 16, 2018
- Completion date
- January 11, 2022
- Enrollment
- 552 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.